Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
Objective To analyze the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and PD-1 antibody in the treatment of intermediate-advanced hepatocellular carcinoma (HCC). Methods A retrospective cohort trial was conducted on 105 patients with interm...
Saved in:
Main Authors: | JIANG Jiayun, ZHANG Hui, ZHANG Shiyu |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Journal of Army Medical University
2024-11-01
|
Series: | 陆军军医大学学报 |
Subjects: | |
Online Access: | https://aammt.tmmu.edu.cn/html/202405116.htm |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01) -
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01) -
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01) -
Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy
by: Lei Liang, et al.
Published: (2024-12-01) -
Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01)